Compare Lennar Corporation (LEN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Lennar (LEN) trades at $73.53, down 1.5% on the day, with a bearish technical signal and recent earnings misses. The homebuilder shows declining revenue and profit margins, with 2025 revenue at $34.19B and net income of $2.08B. Valuation metrics appear attractive with P/E of 14.19 and P/B of 0.83, but cash flow trends show negative net cash flow of -$1.16B in 2025. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.

Lennar presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability, negative cash flow, and housing market challenges. The stock trades below the $77.38 consensus price target, offering potential upside if operational improvements materialize, though execution risks and macroeconomic pressures remain concerns.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.